Registration for ASGCT's 28th Annual Meeting is NOW OPEN! Join us May 13-17 in New Orleans for the premier event in CGT.
In Q3, Tecelra was approved for adults with metastatic synovial sarcoma, newly initiated gene therapy trials increased for non-oncology indications, and seed and Series A funding nearly doubled.
The third quarterly report of 2024 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
Tecelra became the first gene therapy approved for adults with metastatic synovial sarcoma and the first FDA-approved T cell receptor (TCR) gene therapy
The field steadily diversified, with data showing 51% of newly initiated gene therapy trials are for non-oncology indications, up from 39% year-over-year
Seed and Series A funding nearly doubled to $484 million
Download the full report
January 22-23, 2025 | Virtual
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico